

BOARD REGULATION NO. __
Series of 2019

**SUBJECT: RECLASSIFYING MEDICINES CONTAINING CANNABIDIOL
WITH NO MORE THAN 0.1 PERCENT
TETRAHYDROCANNABINOL FROM SCHEDULES 1 AND 2 TO
SCHEDULE 4 OF THE PHILIPPINE SCHEDULE**

WHEREAS, Republic Act No. 9165, or the Comprehensive Dangerous Drugs Act of 2002, as amended (the “Act”), provides that the Dangerous Drugs Board (the “Board”) shall be the policy-making and strategy-formulating body in the planning and formulation of policies and programs on drug prevention and control;

WHEREAS, Section 93 of the Act provides that the Board shall have the power to Reclassify, Add or Remove Any Drug from the List of Dangerous Drugs;

WHEREAS, “extracts and tinctures of cannabis” are listed under Schedule I while “cannabis and cannabis resin” are listed under Schedules I and IV of the 1961 United Nations Single Convention on Narcotic Drugs as amended by the 1972 Protocol (the “1961 UN Convention”);

WHEREAS, tetrahydrocannabinol is listed under Schedule 1 while delta-9-tetrahydrocannabinol is listed under Schedule II of the 1971 United Nations Single Convention on Psychotropic Substances (the “1971 UN Convention”);

WHEREAS, the United States Drug Enforcement Administration has issued an order placing Food and Drug Administration-approved drugs that contain Cannabidiol derived from cannabis and no more than 0.1 percent tetrahydrocannabinols in Schedule V of the United States Controlled Substances Act;

WHEREAS, the United States Food and Drug Administration approved the drug Epidiolex for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome;

WHEREAS, the European Commission and the European Medicines Agency have also approved the marketing authorization for the same drug which allows its distribution throughout Europe;

WHEREAS, the Act states that the government shall aim to achieve a balance in the national drug control program so that people with legitimate medical needs are not prevented from being treated with adequate amounts of appropriate medications, which include the use of dangerous drugs.

WHEREFORE, be it **RESOLVED**, as it is hereby **RESOLVED**, that the Board reclassify medicines containing Cannabidiol with no more than 0.1 percent tetrahydrocannabinol from Schedules 1 (or Schedule IV of the 1961 UN Convention or Schedule I of the 1971 UN Convention) and 2 (or Schedules I and II of the 1961 UN Convention or Schedule II of the 1971 UN Convention) to Schedule 4 of the Philippine Schedule.

WHEREFORE, RESOLVED FURTHER, that medicines containing Cannabidiol with no more than 0.1 percent tetrahydrocannabinol, as part of Schedule 4 of the Philippine Schedule, shall follow the regulatory requirements set forth for Schedule III substances under the 1961 UN Convention.

WHEREFORE, RESOLVED FINALLY, that only physicians with S-2 Licenses and are members of specialty divisions or societies engaged in neurology can prescribe such medicines.

This Regulation shall take effect fifteen (15) days after its publication in two (2) newspapers of general circulation and after its registration with the Office of the National Administrative Register (ONAR), UP Law Center, Quezon City.